Search
Displaying 291–300 of 737 for “retinitis clinical trial”
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Life as a Teen with Retinitis Pigmentosa
Beacon StoriesAt a mere 15 years old, Ava Ruggiero’s world shifted when she received a diagnosis of retinitis pigmentosa. As Ava continues to find balance as a student and athlete, she discusses the challenges of navigating her diagnosis alongside her parents, Joseph and Stephanie.
-
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
Research NewsThe bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
Release Date: June 5, 2020 Expiration Date: May 29, 2023
This activity offers CE credit for: a. Physicians (CME) b. Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
-
Eric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal Research
Research NewsDuring his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
The Super-Sticky Shoes: Living With Retinitis Pigmentosa When the World Can’t See the Glue
Invisible DisabilityIn this deeply personal reflection, author Patti Brite Taylor shares what it feels like to live with retinitis pigmentosa—and how that experience inspired her mystery novel, The Vanishing Cactus, centered on a heroine with low vision.
-
A Gene Therapy Primer for People with Inherited Retinal Diseases
Research NewsEverything patients and families want to know about gene therapy…and a little bit more
-
FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene.
-
Have I Got a Cure for You! Debunking an Alleged Treatment on the Internet
Research NewsHow do you know if a treatment is legit? There should be preclinical and clinical trial data published in a peer-reviewed journal on research for the treatment.
